Cellbion wins South Korea MFDS clearance for phase 3 prostate cancer trial
The trial will enroll 150 patients in Korea and test Lutetium-177 DGUL versus best supportive care or standard of care.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.